People with eosinophilic esophagitis who received the asthma drug Tezspire were far more likely than those on placebo to have their esophageal inflammation under control after a year, according to Phase 3 results released Oct. 20. Between 63% and 68% of treated patients reached tissue remission at 52 weeks, compared with 5.4% on placebo, Reuters reported. At the earlier 24-week checkpoint, remission rates were 64.8% and 68.9%, compared with 3.5% on placebo.
For patients, the question that matters most is swallowing. Eosinophilic esophagitis, or EoE, can make solid food feel stuck in the throat and turn ordinary meals into a source of anxiety. The trial also found improvements in swallowing scores, though the gap compared with placebo was smaller than the remission numbers suggest.
